Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 459

1.

Targeting steroid receptor co-activators to inhibit breast cancer stem cells.

Truong TH, Lange CA, Ostrander JH.

Oncoscience. 2018 Aug 28;5(11-12):281-282. doi: 10.18632/oncoscience.469. eCollection 2018 Nov. No abstract available.

2.

RBL2/p130: a direct AKT substrate and mediator of AKT inhibition-induced apoptosis.

Ventura E, Pentimalli F, Giordano A.

Oncoscience. 2018 Aug 28;5(11-12):278-280. doi: 10.18632/oncoscience.467. eCollection 2018 Nov. No abstract available.

3.

Coaching tumor-infiltrating CD8+ T cells to eat right.

Kurupati R, Ertl HC.

Oncoscience. 2018 Aug 24;5(11-12):276-277. doi: 10.18632/oncoscience.466. eCollection 2018 Nov. No abstract available.

4.

N-MYC regulation of DNA damage response in neuroendocrine prostate cancer: mechanistic insight and novel combination therapy approaches.

Thompson TC, Liu B, Li L.

Oncoscience. 2018 Aug 22;5(11-12):273-275. doi: 10.18632/oncoscience.462. eCollection 2018 Nov. No abstract available.

5.

Origins of ETP leukemia.

Booth CAG, Jacobsen SEW, Mead AJ.

Oncoscience. 2018 Aug 22;5(11-12):271-272. doi: 10.18632/oncoscience.456. eCollection 2018 Nov. No abstract available.

6.

M7824: A promising new strategy to combat cancer immune evasion.

Gatti-Mays ME, Gulley JL.

Oncoscience. 2018 Aug 22;5(11-12):269-270. doi: 10.18632/oncoscience.451. eCollection 2018 Nov. No abstract available.

7.

Regression of primary cardiac angiosarcoma and metastatic nodules following propranolol as a single agent treatment.

Galván DC, Ayyappan AP, Bryan BA.

Oncoscience. 2018 Oct 11;5(9-10):264-268. doi: 10.18632/oncoscience.472. eCollection 2018 Sep.

8.

Reply to: Biological role of miR-204 and miR-211 in melanoma (published in Oncoscience, Vol 5 (7-8), July 2018).

Díaz-Martínez M, Benito-Jardón L, Alonso L, Teixidó J.

Oncoscience. 2018 Nov 9;5(9-10):262-263. doi: 10.18632/oncoscience.473. eCollection 2018 Sep. No abstract available.

9.

ETV4: an emerging target in pancreatic cancer.

Deshmukh SK, Singh AP, Singh S.

Oncoscience. 2018 Oct 11;5(9-10):260-261. doi: 10.18632/oncoscience.471. eCollection 2018 Sep. No abstract available.

10.

TP53 mutation status: emerging biomarker for precision radiation medicine?

Willers H, Wang M, Benes CH.

Oncoscience. 2018 Aug 28;5(9-10):258-259. doi: 10.18632/oncoscience.468. eCollection 2018 Sep. No abstract available.

11.

Risks and chances of aberrant DNA repair in cancer.

Schubert M, Greil R, Geisberger R.

Oncoscience. 2018 Aug 22;5(9-10):256-257. doi: 10.18632/oncoscience.459. eCollection 2018 Sep. No abstract available.

12.

Targeting PIM kinases to oppose hypoxia-mediated therapeutic resistance.

Chauhan SS, Warfel NA.

Oncoscience. 2018 Aug 22;5(9-10):254-255. doi: 10.18632/oncoscience.458. eCollection 2018 Sep. No abstract available.

13.

Re-thinking preclinical models of cancer metastasis.

Ullo MF, Logue JS.

Oncoscience. 2018 Aug 22;5(9-10):252-253. doi: 10.18632/oncoscience.450. eCollection 2018 Sep. No abstract available.

14.

Biological role of miR-204 and miR-211 in melanoma.

Vitiello M, D'Aurizio R, Poliseno L.

Oncoscience. 2018 Aug 22;5(7-8):248-251. doi: 10.18632/oncoscience.443. eCollection 2018 Jul.

15.

A survey of current surgical treatment of early stage breast cancer in China.

Zhang X, Wang Y.

Oncoscience. 2018 Aug 22;5(7-8):239-247. doi: 10.18632/oncoscience.445. eCollection 2018 Jul.

16.

Docetaxel increases the risk of severe infections in the treatment of non-small cell lung cancer: a meta-analysis.

Du Q, Jiang G, Li S, Liu Y, Huang Z.

Oncoscience. 2018 Aug 22;5(7-8):220-238. doi: 10.18632/oncoscience.444. eCollection 2018 Jul.

17.

BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer.

Lochmann TL, Bouck YM, Faber AC.

Oncoscience. 2018 Aug 14;5(7-8):218-219. doi: 10.18632/oncoscience.455. eCollection 2018 Jul. No abstract available.

18.

Proteomics of prostate cancer - revealing how cancer cells master their messy genomes.

Latonen L, Nykter M, Visakorpi T.

Oncoscience. 2018 Jul 31;5(7-8):216-217. doi: 10.18632/oncoscience.453. eCollection 2018 Jul. No abstract available.

19.

Attenuation of YAP1 can potentially target cancer stem cells to overcome drug resistance.

Harada K, Song S, Ajani JA.

Oncoscience. 2018 Aug 22;5(7-8):214-215. doi: 10.18632/oncoscience.449. eCollection 2018 Jul. No abstract available.

20.

Hemangioblast: origin of hemangioblastoma in von Hippel-Lindau (VHL) syndrome.

Wang H, Zhuang Z, Chan CC.

Oncoscience. 2018 Aug 22;5(7-8):212-213. doi: 10.18632/oncoscience.447. eCollection 2018 Jul. No abstract available.

Supplemental Content

Loading ...
Support Center